TrialJournal of neuromuscular diseases2025

Rozanolixizumab in generalized myasthenia gravis: Pooled analysis of the Phase 3 MycarinG study and two open-label extensions.

Vera Bril et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.